Limits...
Dengue Vaccines: A Perspective from the Point of View of Intellectual Property.

da Veiga CP, da Veiga CR, Del Corso JM, da Silva WV - Int J Environ Res Public Health (2015)

Bottom Line: The results show that 93% of patents were granted since 2000, the majority belonging to the United States and Europe, although the share of patents from developing countries has increased.Finally, in this study, the main holders showed high knowledge absorption and generated capabilities.Therefore, this issue suggests that to overcome the difficulty of translational R & D it is necessary to stimulate the generation of knowledge and relevant scientific research, to enable the productive sector to have the capacity to absorb knowledge, to turn it into innovation, and to articulate partnerships and collaboration.

View Article: PubMed Central - PubMed

Affiliation: Pontifical Catholic University of Paraná, PUCPR, Rua Imaculada Conceição, 1155 Prado Velho, 80215-901 Curitiba, PR, Brazil. claudimar.veiga@gmail.com.

ABSTRACT
Dengue is a serious infectious disease and a growing public health problem in many tropical and sub-tropical countries. To control this neglected tropical disease (NTD), vaccines are likely to be the most cost-effective solution. This study analyzed dengue vaccines from both a historical and longitudinal perspective by using patent data, evaluating the geographic and time coverage of innovations, the primary patent holders, the network of cooperation and partnership for vaccine research and development (R & D), the flow of knowledge and the technological domain involved. This study can be seen as an example of the use of patent information to inform policy discussions, strategic research planning, and technology transfer. The results show that 93% of patents were granted since 2000, the majority belonging to the United States and Europe, although the share of patents from developing countries has increased. Unlike another NTDs, there is great participation of private companies in R & D of dengue vaccines and partnerships and collaboration between public and private companies. Finally, in this study, the main holders showed high knowledge absorption and generated capabilities. Therefore, this issue suggests that to overcome the difficulty of translational R & D it is necessary to stimulate the generation of knowledge and relevant scientific research, to enable the productive sector to have the capacity to absorb knowledge, to turn it into innovation, and to articulate partnerships and collaboration.

No MeSH data available.


Related in: MedlinePlus

Distribution of search results by the correlation between first priority year and top 10 holders. Holders: Bavarian Nordic, Centro de Ingenieria Genetica Biotechnologica, Glaxosmithkline Biologicals, Merck Sharp & Dohme, Sanofi Pasteur, Third Military Medical University, US Army, US Department of Health & Human Service, US Government, US Navy.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4555291&req=5

ijerph-12-09454-f006: Distribution of search results by the correlation between first priority year and top 10 holders. Holders: Bavarian Nordic, Centro de Ingenieria Genetica Biotechnologica, Glaxosmithkline Biologicals, Merck Sharp & Dohme, Sanofi Pasteur, Third Military Medical University, US Army, US Department of Health & Human Service, US Government, US Navy.

Mentions: Still, in regards to holders and co-ownership distribution of patent families, Figure 6 illustrates the distribution of search results by the correlation between the first priority year and the top 10 holders. It is possible to note that Bavarian Nordic, the fourth largest holder of the survey data, has made no priority publications since 2002. The US Navy and US Government are in a similar situation and have produced no priority publications since 2006 and 2007, respectively. On the other hand, Glaxosmithkline and Third Military Medical University concentrate their priority publications over the past five years while Sanofi Pasteur and US Department of Health & Human Service show a more uniform distribution of patents over time. These data do not allow making inferences about the continuity of R & D, conducting clinical trials or granting the IP right to a new holder.


Dengue Vaccines: A Perspective from the Point of View of Intellectual Property.

da Veiga CP, da Veiga CR, Del Corso JM, da Silva WV - Int J Environ Res Public Health (2015)

Distribution of search results by the correlation between first priority year and top 10 holders. Holders: Bavarian Nordic, Centro de Ingenieria Genetica Biotechnologica, Glaxosmithkline Biologicals, Merck Sharp & Dohme, Sanofi Pasteur, Third Military Medical University, US Army, US Department of Health & Human Service, US Government, US Navy.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4555291&req=5

ijerph-12-09454-f006: Distribution of search results by the correlation between first priority year and top 10 holders. Holders: Bavarian Nordic, Centro de Ingenieria Genetica Biotechnologica, Glaxosmithkline Biologicals, Merck Sharp & Dohme, Sanofi Pasteur, Third Military Medical University, US Army, US Department of Health & Human Service, US Government, US Navy.
Mentions: Still, in regards to holders and co-ownership distribution of patent families, Figure 6 illustrates the distribution of search results by the correlation between the first priority year and the top 10 holders. It is possible to note that Bavarian Nordic, the fourth largest holder of the survey data, has made no priority publications since 2002. The US Navy and US Government are in a similar situation and have produced no priority publications since 2006 and 2007, respectively. On the other hand, Glaxosmithkline and Third Military Medical University concentrate their priority publications over the past five years while Sanofi Pasteur and US Department of Health & Human Service show a more uniform distribution of patents over time. These data do not allow making inferences about the continuity of R & D, conducting clinical trials or granting the IP right to a new holder.

Bottom Line: The results show that 93% of patents were granted since 2000, the majority belonging to the United States and Europe, although the share of patents from developing countries has increased.Finally, in this study, the main holders showed high knowledge absorption and generated capabilities.Therefore, this issue suggests that to overcome the difficulty of translational R & D it is necessary to stimulate the generation of knowledge and relevant scientific research, to enable the productive sector to have the capacity to absorb knowledge, to turn it into innovation, and to articulate partnerships and collaboration.

View Article: PubMed Central - PubMed

Affiliation: Pontifical Catholic University of Paraná, PUCPR, Rua Imaculada Conceição, 1155 Prado Velho, 80215-901 Curitiba, PR, Brazil. claudimar.veiga@gmail.com.

ABSTRACT
Dengue is a serious infectious disease and a growing public health problem in many tropical and sub-tropical countries. To control this neglected tropical disease (NTD), vaccines are likely to be the most cost-effective solution. This study analyzed dengue vaccines from both a historical and longitudinal perspective by using patent data, evaluating the geographic and time coverage of innovations, the primary patent holders, the network of cooperation and partnership for vaccine research and development (R & D), the flow of knowledge and the technological domain involved. This study can be seen as an example of the use of patent information to inform policy discussions, strategic research planning, and technology transfer. The results show that 93% of patents were granted since 2000, the majority belonging to the United States and Europe, although the share of patents from developing countries has increased. Unlike another NTDs, there is great participation of private companies in R & D of dengue vaccines and partnerships and collaboration between public and private companies. Finally, in this study, the main holders showed high knowledge absorption and generated capabilities. Therefore, this issue suggests that to overcome the difficulty of translational R & D it is necessary to stimulate the generation of knowledge and relevant scientific research, to enable the productive sector to have the capacity to absorb knowledge, to turn it into innovation, and to articulate partnerships and collaboration.

No MeSH data available.


Related in: MedlinePlus